Analisi farmacocinetica ed efficacia virologica di atazanavir a dosaggio ridotto

Translated title of the contribution: Pharmacokinetic exposure and virological efficacy of a reduced atazanavir dose

Massimiliano Lanzafame, Emanuela Lattuada, Fabiana Corsini, Ercole Concia, Sandro Vento

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We report our experience of reduced atazanavir dose in 6 HIV-infected patients on their first antiretroviral regimen, naïve to protease inhibitors and with no PI resistance mutations. In spite of plasmatic trough concentrations of atazanavir below the suggested minimum effective level in all of them, virological suppression (HIV-RNA <50 copies/mL) was obtained and persisted in all patients for a fairly long time. Despite the paucity of cases, this lends weight to the clinical importance of atazanavir MEC which is still being debated.

Original languageItalian
Pages (from-to)293-295
Number of pages3
JournalInfezioni in Medicina
Volume20
Issue number4
Publication statusPublished - Dec 2012
Externally publishedYes

Fingerprint

Pharmacokinetics
HIV
Protease Inhibitors
RNA
Weights and Measures
Mutation
Atazanavir Sulfate

Keywords

  • Atazanavir
  • Ctrough
  • HAART
  • HIV
  • Pharmacokinetics
  • Virological response

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Lanzafame, M., Lattuada, E., Corsini, F., Concia, E., & Vento, S. (2012). Analisi farmacocinetica ed efficacia virologica di atazanavir a dosaggio ridotto. Infezioni in Medicina, 20(4), 293-295.

Analisi farmacocinetica ed efficacia virologica di atazanavir a dosaggio ridotto. / Lanzafame, Massimiliano; Lattuada, Emanuela; Corsini, Fabiana; Concia, Ercole; Vento, Sandro.

In: Infezioni in Medicina, Vol. 20, No. 4, 12.2012, p. 293-295.

Research output: Contribution to journalArticle

Lanzafame, M, Lattuada, E, Corsini, F, Concia, E & Vento, S 2012, 'Analisi farmacocinetica ed efficacia virologica di atazanavir a dosaggio ridotto', Infezioni in Medicina, vol. 20, no. 4, pp. 293-295.
Lanzafame, Massimiliano ; Lattuada, Emanuela ; Corsini, Fabiana ; Concia, Ercole ; Vento, Sandro. / Analisi farmacocinetica ed efficacia virologica di atazanavir a dosaggio ridotto. In: Infezioni in Medicina. 2012 ; Vol. 20, No. 4. pp. 293-295.
@article{bece5455f0b747aca7d74db611ccec9d,
title = "Analisi farmacocinetica ed efficacia virologica di atazanavir a dosaggio ridotto",
abstract = "We report our experience of reduced atazanavir dose in 6 HIV-infected patients on their first antiretroviral regimen, na{\"i}ve to protease inhibitors and with no PI resistance mutations. In spite of plasmatic trough concentrations of atazanavir below the suggested minimum effective level in all of them, virological suppression (HIV-RNA <50 copies/mL) was obtained and persisted in all patients for a fairly long time. Despite the paucity of cases, this lends weight to the clinical importance of atazanavir MEC which is still being debated.",
keywords = "Atazanavir, Ctrough, HAART, HIV, Pharmacokinetics, Virological response",
author = "Massimiliano Lanzafame and Emanuela Lattuada and Fabiana Corsini and Ercole Concia and Sandro Vento",
year = "2012",
month = "12",
language = "Italian",
volume = "20",
pages = "293--295",
journal = "Infezioni in Medicina",
issn = "1124-9390",
publisher = "EDIMES Edizioni Medico Scientifiche",
number = "4",

}

TY - JOUR

T1 - Analisi farmacocinetica ed efficacia virologica di atazanavir a dosaggio ridotto

AU - Lanzafame, Massimiliano

AU - Lattuada, Emanuela

AU - Corsini, Fabiana

AU - Concia, Ercole

AU - Vento, Sandro

PY - 2012/12

Y1 - 2012/12

N2 - We report our experience of reduced atazanavir dose in 6 HIV-infected patients on their first antiretroviral regimen, naïve to protease inhibitors and with no PI resistance mutations. In spite of plasmatic trough concentrations of atazanavir below the suggested minimum effective level in all of them, virological suppression (HIV-RNA <50 copies/mL) was obtained and persisted in all patients for a fairly long time. Despite the paucity of cases, this lends weight to the clinical importance of atazanavir MEC which is still being debated.

AB - We report our experience of reduced atazanavir dose in 6 HIV-infected patients on their first antiretroviral regimen, naïve to protease inhibitors and with no PI resistance mutations. In spite of plasmatic trough concentrations of atazanavir below the suggested minimum effective level in all of them, virological suppression (HIV-RNA <50 copies/mL) was obtained and persisted in all patients for a fairly long time. Despite the paucity of cases, this lends weight to the clinical importance of atazanavir MEC which is still being debated.

KW - Atazanavir

KW - Ctrough

KW - HAART

KW - HIV

KW - Pharmacokinetics

KW - Virological response

UR - http://www.scopus.com/inward/record.url?scp=84875906114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875906114&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 293

EP - 295

JO - Infezioni in Medicina

JF - Infezioni in Medicina

SN - 1124-9390

IS - 4

ER -